Name
Calcilytix, a BridgeBio Company
Description
CALCILYTIX IS DEVELOPING A TARGETED THERAPY FOR DISORDERS OF CALCIUM HOMEOSTASIS.
Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, Hypothesized to restore normal serum calcium and lower urine calcium.
Together with physicians and patients, we aim to develop a safe and effective treatment option for patients with autosomal dominant Hypocalcemia type 1 (ADH1).
Calcilytix is a clinical-stage biopharmaceutical company focused on developing a targeted therapy for disorders of calcium homeostasis. Our product candidate, encaleret, is an investigational orally-administered small molecule designed to specifically inhibit the calcium-sensing receptor, Hypothesized to restore normal serum calcium and lower urine calcium.
Together with physicians and patients, we aim to develop a safe and effective treatment option for patients with autosomal dominant Hypocalcemia type 1 (ADH1).
